|1.||Segal, M: 1 article (11/2000)|
|2.||Prince, W: 1 article (11/2000)|
|3.||Cass, L: 1 article (11/2000)|
|4.||Thomas, S: 1 article (11/2000)|
|5.||Balzarini, J: 1 article (04/2000)|
|6.||De Clercq, E: 1 article (04/2000)|
|7.||Burt, V: 1 article (04/2000)|
|8.||Carbonez, A: 1 article (04/2000)|
|9.||Kleim, J P: 1 article (04/2000)|
04/10/2000 - "Whereas the antiviral efficacy of combinations of GW420867X with the NRTIs lamivudine (3TC) and abacavir (ABC) proved additive when administered to HIV-1-infected cells in a short-term (4-day) infection experiment, combination of GW420867X with the NRTIs 3TC and ABC resulted in a marked delay of virus breakthrough compared with the single drugs alone in a long-term (2-month) infection experiment. "
04/10/2000 - "Our data suggest that combinations of GW420867X with 3TC, ABC, and NNRTIs (e.g., efavirenz) would be worth pursuing as therapeutic modalities against HIV-1 infections."
|2.||HIV Infections (HIV Infection)
11/27/2000 - "This would suggest that GW420867X is a promising drug for the treatment of HIV infection within the brain."
11/27/2000 - "(S)-2-ethyl-7-fluoro-3-oxo-3, 4-dihydro-2H-quinoxaline-carboxylic acid isopropylester (GW420867X) inhibits HIV-1 reverse transcriptase and could be used for the treatment of HIV infection. "
|3.||Human immunodeficiency virus 1 reverse transcriptase